All In Biotech

NDA 020905 · Sanofi Aventis US

Arava

Leflunomide · Oral · Antirheumatic Agent

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jun 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Sep 10, 1998

Approved uses

n/a

Original approval plus efficacy supplements

Registered trials

124

32 Phase 3, 20 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

No approvals could be loaded from Drugs@FDA just now.

Clinical trials

Interventional ClinicalTrials.gov studies with "Leflunomide" as an intervention, any sponsor and status, largest first.

All 124 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Arava (Leflunomide)

2024 spending

$914K

Beneficiaries

93

381 claims

Per beneficiary

$9,830

$47.93 per unit

View as table
YearSpending
2020$941,808
2021$852,155
2022$1,086,920
2023$1,045,335
2024$914,198

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 314 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.